Fri Sep 20 14:16:38 UTC 2024: ## Neumora Therapeutics Stock Rises on Positive Analyst Sentiment

**New York, NY (MarketBeat News) -** Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) closed up 5.2% on Wednesday, reaching $12.34. The stock’s rise was fueled by continued positive analyst sentiment and strong institutional investor interest.

Several analysts have recently issued bullish reports on NMRA. Needham & Company LLC reissued a “buy” rating with a $23.00 target price, while Mizuho initiated coverage with an “outperform” rating and a $20.00 price objective. Royal Bank of Canada reiterated an “outperform” rating and set a $29.00 target price. According to MarketBeat.com, the company has an overall consensus rating of “Moderate Buy” with an average target price of $22.11.

Despite meeting analysts’ expectations for its most recent earnings report, Neumora Therapeutics reported a loss of $0.37 per share for the quarter ending August 6th. However, analysts predict that the company will post a loss of -1.51 EPS for the current year.

While insider trading activity was mixed, with some executives selling shares, several large investors have recently increased their stakes in NMRA. Artal Group S.A., Avidity Partners Management LP, Callan Capital LLC, and Baker BROS. Advisors LP have all made significant investments in the company. Institutional investors now hold 47.65% of the stock.

Neumora Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments for brain diseases. The company’s lead candidate, navacaprant (NMRA-140), is currently in phase 3 clinical trials for the treatment of major depressive disorder.

Investors are optimistic about the company’s potential, with the stock’s recent performance reflecting positive market sentiment. However, it is important to note that the company is still in the early stages of development and its future success is not guaranteed.

Read More